✦ LIBER ✦

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

✍ Scribed by Bradley J. Monk; David C. Choi; Gordon Pugmire; Robert A. Burger

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Corrigendum to “Activity of bevacizumab

✍ Bradley J. Monk; David C. Choi; Gordon Pugmire; Robert A. Burger 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Salvage bevacizumab (rhuMAB VEGF)-based

✍ Bradley J. Monk; Ernest Han; Carol A. Josephs-Cowan; Gordon Pugmire; Robert A. B 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Bevacizumab shows activity in advanced r

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

Bevacizumab displays activity in refract

📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB

RhuMab VEGF (bevacizumab) with concurren

✍ C.H. Crane; L.M. Ellis; M. OReilly; L. Ho; J.L. Abbruzzese; D.B. Evans; C. Ng; C 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 19 KB

Bevacizumab and weekly taxane chemothera

✍ David E. Cohn; Sue Valmadre; Kimberly E. Resnick; Lynne A. Eaton; Larry J. Copel 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 101 KB